Cockayne Syndrome: 7 Essential Facts For 2025

Cockayne syndrome is a rare autosomal recessive disorder characterised by

cachectic dwarfism

,

photosensitivity

,

progressive neurological dysfunction

,

retinal pigmentation

, and

microcephaly

.

• What is Cockayne syndrome? — A multisystem disorder due to defective nucleotide excision repair (NER).
• Who gets Cockayne syndrome (demographics)? — Affects both sexes equally; prevalence ~2.5 per million live births.
• What causes Cockayne syndrome? — Biallelic pathogenic variants in ERCC6/CSB (~70%) or ERCC8/XPA (~30%).
• What are the clinical features of Cockayne syndrome? — Normal birth, postnatal failure to thrive, microcephaly, pigmentary retinopathy, sensorineural deafness, neurodegeneration.
• How is Cockayne syndrome diagnosed? — Clinical features + genetic testing confirming biallelic pathogenic variants.
• How is Cockayne syndrome treated? — Symptomatic and supportive multidisciplinary care.
• What is the prognosis for Cockayne syndrome? — Median survival ~12 years; death often from respiratory infection or neurodegeneration.

What is Cockayne syndrome?

Cockayne syndrome (CS; MIM #278700, #133540) belongs to the spectrum of

DNA repair disorders

caused by defective

nucleotide excision repair (NER)

, the pathway that repairs bulky DNA lesions such as ultraviolet (UV)-induced cyclobutane pyrimidine dimers (CPDs) and (6-4) photoproducts.

CS comprises three overlapping phenotypes:

• **Classic CS (CS1)**: Normal birth followed by postnatal growth failure and neurodegeneration from age 1–2 years.
• **Severe CS (CS2; cerebro-oculo-facio-skeletal [COFS] syndrome)**: Prenatal onset with microcephaly, cataracts, contractures at birth.
• **Enigmatic/mild CS (CS3)**: Late-onset milder neurodegeneration ± photosensitivity.

CS overlaps with xeroderma pigmentosum (XP)-CS complex and UV-sensitive syndrome (UVSS). The hallmark is

transcription-coupled NER (TC-NER)

deficiency, causing prolonged stalling of RNA polymerase II at DNA lesions, leading to

transcription stress

manifesting as premature aging, cachexia, and neurodegeneration.

Who gets Cockayne syndrome (demographics)?

CS affects all ethnicities with equal sex distribution. Prevalence is ~**2–3 per million** live births. Consanguinity increases risk due to autosomal recessive inheritance.

What causes Cockayne syndrome?

CS results from biallelic pathogenic variants in two NER genes:

Complementation group	Gene (protein)	CS frequency	NER subpathway affected
CSA (65–70%)	ERCC8 (CSA)	Classic > mild	TC-NER
CSB (25–30%)	ERCC6 (CSB)	All types	TC-NER >> GG-NER

CSA and CSB proteins interact within the UV-stimulated factor (UVSSA)-centred complex to stabilise stalled RNAPII, facilitating recruitment of TFIIH for lesion verification and repair. CSB additionally links to CSB–CSA–Ubiquitin-E3 ligase complex for histone H2A ubiquitylation and Prot30-mediated RNAPII backtracking.

Rare causes (<1%): MAT1 (MEN1 domain-containing TFIIH subunit), ERCC1, XPG (dual NER/incision genes).

What are the clinical features of Cockayne syndrome?

Growth failure

Postnatal

cachectic dwarfism

is universal, with

birthweight normal

but weight <3rd centile by age 2 years and heightweight plateauing ~100–120 cm >

Neurological features

Progressive

microcephaly

(head circumference <3rd centile by age 2),

cerebral atrophy

(especially white matter),

demyelination

,

basal ganglia calcifications

, and

ventricular dilatation

. Motor milestones delayed (sitting age 1–2 years, walking age 2–5 years or never). Later

ataxia

,

tremor

,

spasticity

,

dystonia

, and loss of ambulation by age 8–12.

Intellectual disability

(IQ 30–50) with expressive > receptive language delay. Epilepsy uncommon.

Cutaneous features

**Cutaneous photosensitivity** without acute burning but with prolonged erythema. Skin becomes

thin, wrinkled, hyperpigmented

(especially face, dorsal hands),

telangiectatic

, and

sclerodermoid

with loss of subcutaneous fat. Hypertrichosis, sparse scalp hair, and

cutis verticis gyrata

(scalp thickening/furrowing) reported.

Ocular features

Progressive

pigmentary retinopathy

(salt-and-pepper fundus) in 80–90%, leading to

visual failure

by age 5–10.

Cataracts

(congenital in CS2),

optic atrophy

,

nystagmus

,

strabismus

,

microphthalmia

, corneal opacities, and enophthalmos (sunken eyes). Photophobia common.

Auditory features

Sensorineural

hearing loss

(mixed conductive in some) progressive from age 2–5 years, severe by adolescence.

Dental features

Enamel hypoplasia, taurodontism, crowded teeth, high caries rate due to xerostomia.

Skeletal features

Premature physeal closure causing

short stature

and

contractures

.

Osteoporosis

,

kyphoscoliosis

, dislocated hips, large hands/feet with joint laxity/contractures, foot deformities.

Other features

• Cardiovascular: Hypertension, atherosclerosis.
• Gastrointestinal: Gastro-oesophageal reflux, poor appetite, failure to thrive.
• Renal: Tubular dysfunction, hypertension.
• Endocrine: Hypogonadism, diabetes.
• Immunological: Normal immunoglobulins, recurrent infections.

Types of Cockayne syndrome

Type	Onset	Severity	Key features	Survival
CS1 (classic)	Age 1–2 yr	Moderate	Normal birth, growth failure, neurodegeneration, retinopathy age 3–5 yr	10–20 yr
CS2 (COFS)	Birth/prenatal	Severe	Microcephaly, contractures, cataracts at birth, no development	<5 yr
CS3 (mild)	Childhood/adolescence	Mild	Late neurodegeneration ± photosensitivity	Adult

Overlap with

XP-CS

(NER deficiency + abnormal pigmentation/carcinomas).

How is Cockayne syndrome diagnosed?

Diagnosis combines:

1. Clinical features: Cachexia + microcephaly + retinopathy + hearing loss + photosensitivity.
2. NER functional studies: Reduced

   unscheduled DNA synthesis (UNS)

   in fibroblasts; absent

   recovery of RNA synthesis (RRS)

   post-UV.
3. Molecular confirmation: NGS panel or whole-exome sequencing for ERCC6/ERCC8 variants.

Prenatal diagnosis: Amniocentesis/CVS for genetic testing if parental variants known.

Differential diagnosis of Cockayne syndrome

• Xeroderma pigmentosum (acute photosensitivity, skin cancers).
• Trichothiodystrophy (brittle hair, ichthyosis).
• COFS syndrome (now CS2).
• Mitochondrial disorders (e.g. Pearson, Kearns–Sayre).
• Mucopolysaccharidoses, Hallermann–Streiff syndrome.

Investigations for Cockayne syndrome

• Brain MRI: White matter loss, basal ganglia calcification.
• Ophthalmology: Fundoscopy, visual evoked potentials.
• Audiometry: Sensorineural loss.
• Fibroblast UNS/RRS: Confirm NER defect.
• Genetic testing: Confirm biallelic variants.

How is Cockayne syndrome managed?

Multidisciplinary supportive care:

• Photoprotection: SPF50+ broad-spectrum sunscreen, UPF50+ clothing, hats.
• Nutrition: High-calorie supplements, gastrostomy if needed.
• Physiotherapy/OT: Maintain mobility, prevent contractures.
• Ophthalmology/ENT: Cataract surgery, hearing aids/cochlear implants.
• Dentistry: Fluoride, fissure sealants.
• Neurology: Antispasticity agents (baclofen), seizure control if needed.
• Palliative care: Respiratory support, pain management.

Experimental: Antioxidants, NAD+ precursors unproven.

What is the prognosis for Cockayne syndrome?

CS1 median survival

12 years

(range 5–20); CS2 <7 years. Death from

respiratory failure

,

infection

, or

bulbar dysfunction

. CS3 may reach adulthood with milder disability.

Prevention and screening for Cockayne syndrome

Genetic counselling for carriers. Prenatal diagnosis available.

Cockayne syndrome FAQs

What is the life expectancy for Cockayne syndrome?

Average 12 years for classic CS1, shorter for severe CS2 (<7 years).

Is Cockayne syndrome curable?

No cure; only supportive care available.

Does Cockayne syndrome cause skin cancer?

Rare (unlike XP); focus on photoprotection to prevent burns.

Can Cockayne syndrome be detected prenatally?

Yes, via amniocentesis if family history/genetic risk.